skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

About Clara

San Diego, USA

+3 year(s) experience

Clara Tan - Biomedtracker - Pharmaintelligence
Analyst II Clara Tan maintains the Biomedtracker database, managing coverage of neurological diseases. She has also authored a biosimilars report and is the maintain point of contact for questions on this topic area.

Since joining Pharma Intelligence in 2013, Clara has developed a strong understanding of clinical drug development and its role with regulatory bodies. She is passionate about
drug development 
and the idiosyncrasies of every disease area.

Her Biosimilars Special Report, demonstrated the unknowns of a new regulatory pathway that parallels the introduction of Hatch-Waxman generic drugs in 1984. The report accompanied a Reimbursement Key Opinion Leader Interview, where she also explored the impact of biosimilars on the regulatory space.


Analyst Articles

Articles by Clara

  • Competitive and market intelligence Business development and licensing Regulatory approval

    Biomedtracker

    Biomedtracker Analysts Dissect the US Biosimilar Pathway

    By Clara Tan 16 Sep 2015

    The enactment of the US FDA Biosimilar 351(k) pathway in March 2010 has created uncertainty on many fronts. The innovator, biosimilar developer, FDA, and payer have spent years readjusting their strategies to prepare for the introduction of biosimilars in the US.

    Topics FDA Biosimilars

;